Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 1/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.55 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | PTH1R | Q03431 | 6/20 | 0.52 |
| ▸ | CCKBR | P32239 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30544197 | 0.86 | CXCR4 (0.55) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30497472 | 0.86 | CXCR4 (0.55) | CXCR4C5AR1CCKBROPRD1TACR1 | |
| SCHEMBL30648474 | 0.86 | NPY1R (0.66) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29695518 | 0.85 | CXCR4 (0.64) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30767709 | 0.85 | GLP1R (0.61) | CXCR4C5AR1CCKBR | |
| SCHEMBL31013465 | 0.85 | CXCR4 (0.56) | CXCR4C5AR1OPRD1PCSK9 | |
| SCHEMBL29602399 | 0.85 | KISS1R (0.65) | CXCR4C5AR1TACR1KISS1R | |
| SCHEMBL30665991 | 0.85 | CXCR4 (0.60) | CXCR4C5AR1OPRD1TACR1 | |
| SCHEMBL31606485 | 0.85 | CXCL8 (0.56) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31606491 | 0.85 | C5AR1 (0.61) | CXCR4NPY1RNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120124945-A | Intelligent planning method for geological mineral exploration analysis model | 山东省地质矿产勘查开发局第六地质大队(山东省第六地质矿产勘查院) | 2025-06-10 | — | — | CN | claimed |
| EP-3886318-B1 | CURRENT MIRROR ARRANGEMENTS WITH ADJUSTABLE OFFSET BUFFERS | ANALOG DEVICES INC (US) | 2025-03-12 | — | — | EP | claimed |
| US-11639371-B2 | Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2023-05-02 | — | — | US | claimed |
| CN-113448375-B | Current mirror arrangement with adjusted offset buffer | 美国亚德诺半导体公司 | 2023-02-28 | — | — | CN | claimed |
| US-11352397-B2 | Genetic reprogramming of bacterial biofilms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-06-07 | — | — | US | claimed |
| CN-115836129-B | Compositions and methods for treating TDP-43 proteinopathies | Sola Biosciences Ltd. (US) | 2026-05-26 | — | — | CN | disclosed |
| US-12631921-B2 | Display device and display system | MAGNOLIA WHITE CORPORATION (JP) | 2026-05-19 | — | — | US | disclosed |
| WO-2026027088-A1 | QBP1 FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2026-02-05 | — | — | WO | disclosed |
| WO-2026027088-A1 | QBP1 FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2026-02-05 | — | — | WO | disclosed |
| EP-4686478-A1 | QBP1 FOR USE IN THE TREATMENT AND/OR PREVENTION OF TYPE 2 DIABETES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2026-02-04 | — | — | EP | disclosed |
| EP-4686478-A1 | QBP1 FOR USE IN THE TREATMENT AND/OR PREVENTION OF TYPE 2 DIABETES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2026-02-04 | — | — | EP | disclosed |
| EP-4686478-A1 | QBP1 FOR USE IN THE TREATMENT AND/OR PREVENTION OF TYPE 2 DIABETES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2026-02-04 | — | — | EP | disclosed |
| US-20220315935-A1 | ENGINEERED YEAST FOR NONMAGNETIC FINES RECOVERY | GREENE ROBERT CRANDALL (CA) | 2022-10-06 | — | — | US | disclosed |
| US-11352397-B2 | Genetic reprogramming of bacterial biofilms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-06-07 | — | — | US | disclosed |
| WO-2022093736-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SOLA BIOSCIENCES LLC (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3279942-B1 | RANGE SENSOR | UNIV SHIZUOKA NAT UNIV CORP (JP) | 2022-05-04 | — | — | EP | disclosed |
| CN-113783273-B | Battery string rapid self-balancing charge-discharge protection circuit and control method | 湖南九州节能科技有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11286491-B2 | Biosynthetic amyloid-based materials displaying functional protein sequences | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-29 | — | — | US | disclosed |
| WO-2022061378-A2 | METHODS FOR TREATING NEUROLOGICAL DISEASE | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022051673-A1 | HUNTINGTIN-RELATED PEPTIDE AGENTS AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12631921-B2 | Display device and display system | PTP4A2, PTP4A1, PTP4A3 | CXCR4 1025/4885NPY1R 2356/4885NPY2R 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.